UCB joins Future4care!
Paris, May 12th, 2022. UCB, an international biopharmaceutical company specialized and recognized in severe diseases in immunology and neurology, joins Future4care as a new member.
Published on May 11th, 2022 at 06:59 a.m.
The arrival of this Belgian biopharmaceutical pioneer, with more than 8,500 employees worldwide, reinforces the multidisciplinary approach sought by Future4care's founders.
Joining Future4care illustrates UCB's commitment to proactive innovation. We share a common belief that we cannot solve the world's healthcare challenges alone, and that major breakthroughs will come from the use of new technologies and open collaboration. That's why the partnership approach is at the heart of UCB's drive to discover new tools, technologies and partners to connect with patients.
Fabienne Delaplace-Lavoix, General Manager of UCB France explains that "UCB is extremely proud to join the Future4care community to accelerate the delivery of new healthcare solutions and meet new patient needs. It is by joining forces - dynamic companies, startups in Biotech and Medtech and the pharmaceutical industry - that we can unleash the power of innovation and, together, invent the future of our healthcare. Our mission is to create value for patients. And I think we've all understood that patient value calls on us to invent new possibilities."
As a member of the Future4care Selection Committee, UCB will play a fundamental role in the ecosystem's governance, in order to :
Define Future4care's annual themes and illustrations;
Participate in the choice of selection criteria for selected startups;
Help set the guidelines for the work of the Future4care Institute;
Contribute to the entry of new members.
UCB will also take part in the selection of startups for the various calls for projects launched every six months.
The new member will also benefit from access to the Future4care open innovation platform and a range of acculturation, collaboration and influence services.
They will also be invited to contribute to the work of the Future4care Institute.
For more information, visit https://future4care.com
About Future4care
Future4care is the European e-health start-up gas pedal, born of an alliance between Capgemini, Generali, Orange and Sanofi. Its purpose is to accelerate the market launch of solutions capable of becoming European e-health champions. Future4care is a unique ecosystem in Europe:
A 6400m2 space in the heart of Paris, in the 13th district, in the Biopark, to support start-ups in their acceleration phase;
An open innovation platform to facilitate acculturation, collaboration and influence within the community.
An Institute, a true knowledge center, offering programs and conferences related to digital health;
A benchmark label.
About UCB
At UCB, our mission is never finished - because we always aspire to find new ways to develop solutions for people living with serious diseases. We act with determination to create value and make real improvements in the lives of the people we serve, now and in the future. We are guided by our commitment to people living with serious illness, who inspire our research and development in neurology, immunology and other areas where our expertise, innovation and ambition can address unmet needs. We build strong links with the patients and healthcare professionals who face these diseases every day, as well as with colleagues and partners who share our passion for tackling the challenges of severe disease.
Press contact :
Future4care
Vincent Puren
UCB France
Flore Houlet
